Bendamustine hydrochloride - CAS 3543-75-7
Catalog number: 3543-75-7
Category: Inhibitor
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
Molecular Weight:
Bendamustine hydrochloride is the hydrochloride salt of bendamustine, a bifunctional mechlorethamine derivative with alkylator and antimetabolite activities. Bendamustine possesses three active moieties: an alkylating group; a benzimidazole ring, which may act as a purine analogue; and a butyric acid side chain. Although its exact mechanism of action is unknown, this agent appears to act primarily as an alkylator. Bendamustine metabolites alkylate and crosslink macromolecules, resulting in DNA, RNA and protein synthesis inhibition, and, subsequently, apoptosis. Bendamustine may differ from other alkylators in that it may be more potent in activating p53-dependent stress pathways and inducing apoptosis; it may induce mitotic catastrophe; and it may activate a base excision DNA repair pathway rather than an alkyltransferase DNA repair mechanism.
Publictions citing BOC Sciences Products
  • >> More
SDX-105 (Cytostasane) HCl
1.Bendamustine in combination with rituximab for elderly patients with previously untreated B-cell chronic lymphocytic leukemia: A retrospective analysis of real-life practice in Italian hematology departments.
Laurenti L1, Innocenti I2, Autore F2, Vannata B3, Efremov DG4, Ciolli S5, Del Poeta G6, Mauro FR7, Cortelezzi A8, Borza PA9, Ghio F10, Mondello P11, Murru R12, Gozzetti A13, Cariccio MR14, Piccirillo N2, Boncompagni R5, Cantonetti M6, Principe MI6, Reda G Leuk Res. 2015 Oct;39(10):1066-70. doi: 10.1016/j.leukres.2015.07.009. Epub 2015 Jul 26.
The front-line therapy for CLL young and fit patients is chemo-immunotherapy with fludarabine-cyclophosphamide-rituximab (FCR). FCR regimen results in a significant myelosuppression and high rates of early and late infections especially in elderly patients. German CLL study group compared FCR vs. bendamustine-rituximab (BR) in fit untreated patients. The response rates with BR or FCR were comparable, BR could be an alternative 1st-line treatment for elderly patients. Here we report retrospective data of 70 elderly (≥65 years) CLL patients from 12 Italian centers treated with BR as front-line therapy. The primary end points were overall response rate (complete remission/partial remission) and safety. Forty-seven males and 23 females, with a median age of 72 years, were included in the study. Eight patients were unfit for CIRS. The OR rate was 88.6% (31.4% CR and 57.2% PR). Progression free survival, treatment free survival and overall survival rates at 2-years were 79%, 90.
2.Phase I/IIa study of sequential chemotherapy regimen of bendamustine/irinotecan followed by etoposide/carboplatin in untreated patients with extensive disease small cell lung cancer (EDSCLC).
Allendorf DJ1, Bordoni RE2, Grant SC3, Saleh MN4, Reddy VB5, Jerome ML6, Dixon PM7, Miley DK6, Singh KP8, Robert F9. Cancer Chemother Pharmacol. 2015 Nov;76(5):949-55. doi: 10.1007/s00280-015-2869-6. Epub 2015 Sep 22.
PURPOSE: The sequence bendamustine (B) + Irinotecan (I) followed by etoposide (E) + carboplatin (C) was hypothesized to increase progression-free survival (PFS) and overall survival (OS) in untreated extensive-disease small cell lung cancer (EDSCLC) patients compared to historical controls by exploiting mitotic catastrophe. Absent expression of ERCC-1 and expression of topoisomerases were hypothesized to be predictive for PFS and OS.
3.Phase II study of bendamustine combined with rituximab in relapsed/refractory mantle cell lymphoma: efficacy, tolerability, and safety findings.
Czuczman MS1, Goy A2, Lamonica D3, Graf DA3,4, Munteanu MC5, van der Jagt RH6. Ann Hematol. 2015 Dec;94(12):2025-32. doi: 10.1007/s00277-015-2478-9. Epub 2015 Sep 28.
In most cases of relapsed/refractory mantle cell lymphoma (MCL), patients respond to salvage therapy, though typically responses are partial and/or transient followed by disease progression, even with newer agents (e.g., ibrutinib). In this multicenter, open-label, single-arm, phase II study, patients with relapsed/refractory non-blastoid MCL received bendamustine 90 mg/m(2) (days 1 and 2) and rituximab 375 mg/m(2) (day 1) for 6 planned 28-day cycles. Functional imaging with 18-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography (18F-FDG PET/CT) was conducted at baseline and after cycle 6. Forty-five patients were enrolled (median age, 70 years; 82 % stage IV disease; median number of prior chemotherapies, 2 [range, 1-4]), showing an overall response rate (ORR; primary efficacy measure) of 82 % (complete response [CR], 40 %; partial response, 42 %). In the 32 patients with complete 18F-FDG PET/CT data, 75 % achieved a complete metabolic response.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Products

CAS 26328-04-1 Cinepazide maleate

Cinepazide maleate
(CAS: 26328-04-1)

Cinepazide maleate is a maleate salt form of cinepazide which is a vasodilator.

(CAS: 400797-24-2)

JNJ-10329670 represents a novel class of immunosuppressive compounds with a highly potent (Ki ~30 nM)

CAS 87-89-8 Inositol

(CAS: 87-89-8)

Inositol is a chemical compound found in many foods, especially oranges and cantaloupe. It is well-absorbed and relatively bioavailable. It is a component of me...

CAS 144675-97-8 Pixantrone Maleate

Pixantrone Maleate
(CAS: 144675-97-8)

Pixantrone is a synthetic, noncardiotoxic aza-anthracenedione analogue with potential antineoplastic activity. Pixantrone intercalates into DNA and induces topo...

(CAS: 317846-22-3)

JNJ-2408068 is a potent inhibitor of respiratory syncytial virus (RSV), exhibits potent antiviral activity with 50% effective concentrations (EC50s) of 1.4 and ...

CAS 107767-58-8 A-802715

(CAS: 107767-58-8)

A802715, a methylxanthine derivative, is an anti-tumor agent with a TD50 (toxic dose of 50%) of 0.9-1.1 mM.

CAS 87860-39-7 Fostriecin sodium salt

Fostriecin sodium salt
(CAS: 87860-39-7)

Fostriecin sodium salt is a protein phosphatase types 2A (PP2A) and 4 (PP4) inhibitor (IC50 = 1.5 nM and 3 nM, respectively). It also has an inhibitory effect o...

(CAS: 756500-23-9)

Cyclo(RADfK) is a selective α(v)β(3) integrin ligand. It has been used for research, therapy, and diagnosis of neoangiogenesis. It is also used as a negative co...

CAS 9041-08-1 Heparin sodium

Heparin sodium
(CAS: 9041-08-1)

Heparin sodium is a sodium salt of heparin which is a naturally-occurring anticoagulant used for anticoagulation for cardiovascular disease. It is an inhibitor ...

CAS 109552-15-0 Pamidronate disodium pentahydrate

Pamidronate disodium pentahydrate
(CAS: 109552-15-0)

Pamidronate disodium pentahydrate is a nitrogen-containing bisphosphonate, used to prevent osteoporosis.

CAS 43218-56-0 Midodrine (hydrochloride)

Midodrine (hydrochloride)
(CAS: 43218-56-0)

Midodrine is an α1-receptor agonist and exerts its actions via activation of the alpha-adrenergic receptors of the arteriolar and venous vasculature.

CAS 1202193-89-2 ThioLox

(CAS: 1202193-89-2)

ThioLox is an inhibitor of 15-lipoxygenase-1 (15-LOX-1) with both anti-inflammatory and neuroprotective properties (IC50 value of 12 µM). 15-LOX-1 is involved i...

CAS 63547-13-7 Adrafinil

(CAS: 63547-13-7)

Adrafinil, prodrug of modafinil, is a mild central nervous system stimulant drug used to relieve excessive sleepiness and inattention. It is believed to serve a...

(CAS: 314289-63-9)

A bio-active organic chemical.

CAS 442201-24-3 Remogliflozin etabonate

Remogliflozin etabonate
(CAS: 442201-24-3)

Remogliflozin etabonat, pro-drug of remogliflozin, is a SGLT2 inhibitor under development for the treatment of type 2 diabetes. Remogliflozin etabonate is a pr...

CAS 120-47-8 4-Hydroxybenzoic Acid Ethyl Ester

4-Hydroxybenzoic Acid Ethyl Ester
(CAS: 120-47-8)

4-Hydroxybenzoic Acid Ethyl Ester could be commonly used in cosmetic products as an antimicrobial agent.

CAS 102841-42-9 Mulberroside A

Mulberroside A
(CAS: 102841-42-9)

Mulberroside A, extracted from the root bark of white mulberry, could reduce P-gp expression and function being along with the activation of PKC and NF-κB. It h...

(CAS: 1251537-11-7)

Navamepent is an inflammation mediator inhibitor and lipid modulator originated by Resolvyx Pharmaceuticals and licensed to Auven Therapeutics in 2011. Treatmen...

CAS 1439934-41-4 CTX-0294885

(CAS: 1439934-41-4)

CTX-0294885 is a novel broad-spectrum kinase inhibitor. CTx-0294885 exhibits inhibitory activity against a broad range of kinases in vitro. Use of a quantitativ...

CAS 116714-46-6 Novaluron

(CAS: 116714-46-6)

Novaluron is a chemical with pesticide properties, belonging to the class of insecticides called insect growth regulators. It inhibits chitin formation, targeti...

Chemical Structure

CAS 3543-75-7 Bendamustine hydrochloride

Quick Inquiry

Verification code

Featured Items